Three Republican-led US states are turning to an unusual legal strategy to restrict access to abortion pills, arguing that doctors who send the medication across state lines are creating a “public nuisance” by undermining their abortion bans.
Louisiana, Alabama and Arkansas have launched two lawsuits targeting medical providers and states that protect abortion services through special legal safeguards. The cases challenge the practices of doctors who prescribe abortion medication remotely and mail it to patients in states where abortion is prohibited.
The lawsuits name New York, California and Massachusetts, which have enacted shield laws designed to protect abortion providers from out-of-state criminal charges and civil lawsuits arising from care that is legal within their jurisdictions.
The strategy marks a new front in the widening US abortion dispute. Legal experts say using public nuisance law to restrict access to medication abortion is an unprecedented move, as the doctrine has traditionally been invoked in cases involving environmental pollution and other threats to public health.
It also represents the first direct challenge by abortion-ban states to shield laws adopted by states seeking to protect reproductive healthcare providers.
A new legal route to restrict abortion access
The latest lawsuits come as opponents of abortion seek to counter the growing use of telehealth services to obtain abortion medication. According to the Guttmacher Institute, approximately 91,000 abortions were provided through telehealth in 2025 to patients living in states with total abortion bans, up from 74,000 the previous year.
New York Attorney General Letitia James and Massachusetts Attorney General Andrea Joy Campbell criticised the legal action, arguing that the Republican-led states were attempting to extend their abortion restrictions beyond their own borders and penalise doctors for providing lawful medical care.
California Attorney General Rob Bonta’s office did not immediately comment on the litigation.
The legal dispute follows years of efforts by states opposed to abortion to restrict access to medication after the US Supreme Court overturned Roe v. Wade in 2022, ending the nationwide constitutional protection for abortion that had existed since 1973.
Nearly half of US states have since banned abortion or imposed severe restrictions. As a result, patients in those states increasingly rely on travelling elsewhere or obtaining medication through remote consultations and mail delivery.
Medication abortion typically involves two drugs, mifepristone and misoprostol, used together to terminate a pregnancy during its early stages. The method has become a major component of abortion care in the United States.
Federal approval adds another layer to the dispute
Republican-led states have pursued several legal avenues to restrict access to abortion medication, including lawsuits against doctors and challenges to the federal approval of mifepristone and regulations that expanded its availability.
In May, the Supreme Court declined Louisiana’s request to block nationwide telehealth prescribing and mail delivery of mifepristone while a separate legal challenge over the drug’s regulation continued.
Meanwhile, the US Food and Drug Administration is conducting a safety review of the medication. In a court filing, the agency said it expects to complete the review by March 2027, a timeline that has drawn criticism from some anti-abortion groups.
Major medical organisations and federal regulators have repeatedly maintained that mifepristone is safe and effective when used as directed, with serious adverse events considered rare.
Can abortion pills qualify as a public nuisance?
Public nuisance law generally addresses activities that unreasonably threaten public health, safety or the use of shared spaces. Examples include obstructing roads, contaminating waterways and releasing harmful fumes.
Over the years, the legal doctrine has also featured in lawsuits involving tobacco, opioids, vaping, climate change and the effects of social media on children.
One reason plaintiffs turn to this approach is that it can allow courts to issue broad orders requiring defendants to stop or correct allegedly harmful activities. Depending on the circumstances, it may also provide a way around certain traditional requirements for establishing legal standing and proving individual harm.
However, the abortion-related claims raise a fundamental question: can states use a doctrine designed to address public harms to prevent the distribution of a medication that federal regulators have repeatedly approved?
Critics argue that the lawsuits are less about protecting public health than about enforcing state abortion prohibitions beyond their borders.
Linda Goldstein, senior counsel at the Center for Reproductive Rights, said the claims depart from the conventional purpose of public nuisance law because they do not fit the usual model of protecting residents from tangible public harm.
The states pursuing the cases take a different position. In their court filings, they argue that out-of-state providers and the laws shielding those providers are interfering with their ability to enforce abortion restrictions enacted in the name of public safety.
To support their argument, the states compared the alleged conduct to hypothetical situations in which other states encouraged residents to send dangerous substances or explosives into jurisdictions where such conduct was prohibited.
Two lawsuits, two legal fronts
One of the cases, brought directly before the US Supreme Court, challenges the shield laws adopted by states protecting abortion providers. The Supreme Court has the authority to hear certain disputes between states without requiring them to begin in lower courts, although it frequently declines to take up such cases.
The second lawsuit was filed in a federal court in Louisiana and names nearly 30 individual medical practitioners and organisations as defendants. Both cases raise additional legal claims alongside the public nuisance arguments.
The three states’ attorney general offices did not respond to requests for comment. Two nonprofit organisations named in the Louisiana case, A Safe Choice Network and Cambridge Reproductive Health Consultants, also did not immediately comment.
The outcome could have significant implications for the growing conflict between states that prohibit abortion and those attempting to preserve access to reproductive healthcare. Beyond the immediate dispute over medication, the courts may have to determine how far one state’s abortion restrictions can reach when medical treatment is legally provided from another state.
For now, the public nuisance argument offers abortion-ban states a fresh legal avenue to test. Whether courts accept that approach could shape the future of telehealth abortion services and the protections available to providers operating across state lines.
